ReviewMedicine2026
Pyroptosis in cardiovascular diseases: A bibliometric insight into current research and future directions.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPyroptosis, a unique form of programmed cell death, has emerged as an area of keen interest in cardiovascular disease (CVD) research. This study mapped the knowledge structure, research trends, and emerging directions of pyroptosis research in CVD.
methodsWe performed a bibliometric analysis of English-language articles and reviews on pyroptosis in CVD published in the Web of Science Core Collection from January 1, 2006, to September 30, 2023. After independent eligibility assessment by 2 reviewers, the records were analyzed using VOSviewer, CiteSpace, and the bibliometrix R package. A targeted PubMed search conducted on July 30, 2026, was used only to contextualize representative developments published after the bibliometric cutoff.
resultsWe identified 3337 studies and reviews addressing pyroptosis in the context of CVD from 2006 to September 30, 2023. The analysis revealed that China had the highest number of publications, whereas the United States exhibited a more substantial impact in the field. Network analysis showed robust collaborative networks, particularly among the United States, China, and several European countries, with the top 10 contributing institutions hailing from the United States and China. Term frequency analysis identified "NLRP3 inflammasome," "pyroptosis," and "inflammation" as the most frequent keywords.
conclusionThis bibliometric analysis provides a reproducible historical baseline of cardiovascular pyroptosis research through September 2023. A targeted post-cutoff update indicates that subsequent work has increasingly focused on cell-specific gasdermin D and gasdermin E execution, immunometabolic and post-translational regulation, multimodal profiling, and direct gasdermin inhibition. These developments strengthen the trends identified in the original networks, while the continued predominance of preclinical evidence underscores the need for pathway-specific biomarkers and clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.